Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Logo for

PNAS 104 (9): 3456-3459

Copyright © 2007 by the National Academy of Sciences.

From the Cover


Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase

Sangwon F. Kim*, Alex S. Huang*, Adele M. Snowman*, Cory Teuscher{dagger}, and Solomon H. Snyder*,{ddagger},§

*The Solomon H. Snyder Department of Neuroscience, Departments of {ddagger}Pharmacology and Molecular Sciences and §Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, 725 North Wolfe Street, Baltimore, MD 21205; and {dagger}Departments of Medicine and Pathology, University of Vermont College of Medicine, 89 Beaumont Avenue, Burlington, VT 05405

Contributed by Solomon H. Snyder, December 21, 2006

Received for publication November 28, 2006.

Abstract: The atypical antipsychotic drugs (AAPDs) have markedly enhanced the treatment of schizophrenias but their use has been hindered by the major weight gain elicited by some AAPDs. We report that orexigenic AAPDs potently and selectively activate hypothalamic AMP-kinase, an action abolished in mice with deletion of histamine H1 receptors. These findings may afford a means of developing more effective therapeutic agents and provide insight into the hypothalamic regulation of food intake.

Key Words: atypical antipsychotic drugs • obesity • hypothalamus

Author contributions: S.F.K. designed research; S.F.K., A.S.H., and A.M.S. performed research; C.T. contributed new reagents/analytic tools; S.F.K., A.S.H., and S.H.S. analyzed data; and S.F.K. and S.H.S. wrote the paper.

The authors declare no conflict of interest.

See Commentary on page 3019.

This article contains supporting information online at

To whom correspondence should be addressed. E-mail: ssnyder{at}

© 2007 by The National Academy of Sciences of the USA

Second-Generation Antipsychotics Cause a Rapid Switch to Fat Oxidation That Is Required for Survival in C57BL/6J Mice.
C. M. Klingerman, M. E. Stipanovic, M. Bader, and C. J. Lynch (2014)
Schizophr Bull 40, 327-340
   Abstract »    Full Text »    PDF »
G Proteins G{alpha}i1/3 Are Critical Targets for Bordetella pertussis Toxin-Induced Vasoactive Amine Sensitization.
S. A. Diehl, B. McElvany, R. Noubade, N. Seeberger, B. Harding, K. Spach, C. Teuscher, and S. R. Blanke (2014)
Infect. Immun. 82, 773-782
   Abstract »    Full Text »    PDF »
Olanzapine Activates Hepatic Mammalian Target of Rapamycin: New Mechanistic Insight into Metabolic Dysregulation with Atypical Antipsychotic Drugs.
R. H. Schmidt, J. D. Jokinen, V. L. Massey, K. C. Falkner, X. Shi, X. Yin, X. Zhang, J. I. Beier, and G. E. Arteel (2013)
J. Pharmacol. Exp. Ther. 347, 126-135
   Abstract »    Full Text »    PDF »
Histamine and antipsychotic drug-induced weight gain.
G. P. Reynolds (2012)
J Psychopharmacol 26, 1608-1609
   Full Text »    PDF »
Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model.
C. Deng, J. Lian, N. Pai, and X.-F. Huang (2012)
J Psychopharmacol 26, 1271-1279
   Abstract »    Full Text »    PDF »
Review: metformin is effective at attenuating the metabolic risks associated with use of atypical antipsychotics.
D. J. Klein and S. N. Saldana (2011)
Evid. Based Ment. Health 14, 55
   Full Text »    PDF »
Atypical antipsychotic drugs perturb AMPK-dependent regulation of hepatic lipid metabolism.
K.-J. Oh, J. Park, S. Y. Lee, I. Hwang, J. B. Kim, T.-S. Park, H.-J. Lee, and S.-H. Koo (2011)
Am J Physiol Endocrinol Metab 300, E624-E632
   Abstract »    Full Text »    PDF »
The Histamine H3 Receptor and Eating Behavior.
M. B. Passani, P. Blandina, and F. Torrealba (2011)
J. Pharmacol. Exp. Ther. 336, 24-29
   Abstract »    Full Text »    PDF »
Acute effects of betahistine hydrochloride on food intake and appetite in obese women: a randomized, placebo-controlled trial.
A. H. Ali, L. B. Yanoff, E. A. Stern, A. Akomeah, A. Courville, M. Kozlosky, S. M. Brady, K. A. Calis, J. C. Reynolds, M. K. Crocker, et al. (2010)
Am J Clin Nutr 92, 1290-1297
   Abstract »    Full Text »    PDF »
Central Nervous System Delivery of the Antipsychotic Olanzapine Induces Hepatic Insulin Resistance.
P. J. F. Martins, M. Haas, and S. Obici (2010)
Diabetes 59, 2418-2425
   Abstract »    Full Text »    PDF »
Clozapine-associated weight loss.
R. Hanwella, V. de Silva, C. Wijeratne, T. Ketharanathan, and J. de Silva (2010)
J Psychopharmacol 24, 1127-1129
   Abstract »    PDF »
A Novel Multilevel Statistical Method for the Study of the Relationships between Multireceptorial Binding Affinity Profiles and In Vivo Endpoints.
J. Selent, A. Bauer-Mehren, L. Lopez, M. I. Loza, F. Sanz, and M. Pastor (2010)
Mol. Pharmacol. 77, 149-158
   Abstract »    Full Text »    PDF »
Secondary Effects of Antipsychotics: Women at Greater Risk Than Men.
M. V. Seeman (2009)
Schizophr Bull 35, 937-948
   Abstract »    Full Text »    PDF »
Antagonism of dopamine D2 receptor/{beta}-arrestin 2 interaction is a common property of clinically effective antipsychotics.
B. Masri, A. Salahpour, M. Didriksen, V. Ghisi, J.-M. Beaulieu, R. R. Gainetdinov, and M. G. Caron (2008)
PNAS 105, 13656-13661
   Abstract »    Full Text »    PDF »
Olanzapine (LY170053, 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] Benzodiazepine), but Not the Novel Atypical Antipsychotic ST2472 (9-Piperazin-1-ylpyrrolo[2,1-b][1,3]benzothiazepine), Chronic Administration Induces Weight Gain, Hyperphagia, and Metabolic Dysregulation in Mice.
R. Coccurello, A. Caprioli, R. Conti, O. Ghirardi, F. Borsini, P. Carminati, and A. Moles (2008)
J. Pharmacol. Exp. Ther. 326, 905-911
   Abstract »    Full Text »    PDF »
Histamine in the Nervous System.
H. L. Haas, O. A. Sergeeva, and O. Selbach (2008)
Physiol Rev 88, 1183-1241
   Abstract »    Full Text »    PDF »
Antipsychotic Induced Weight Gain in Schizophrenia: Mechanisms and Management.
S. Rege (2008)
Australian and New Zealand Journal of Psychiatry 42, 369-381
   Abstract »    Full Text »    PDF »
S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], A Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent: I. Receptor-Binding Profile and Functional Actions at G-Protein-Coupled Receptors.
M. J. Millan, C. M. la Cour, F. Novi, R. Maggio, V. Audinot, A. Newman-Tancredi, D. Cussac, V. Pasteau, J.-A. Boutin, T. Dubuffet, et al. (2008)
J. Pharmacol. Exp. Ther. 324, 587-599
   Abstract »    Full Text »    PDF »
Bipolar Disorder and Weight Gain: A Multifactorial Assessment.
S. Simmons-Alling and S. Talley (2008)
Journal of the American Psychiatric Nurses Association 13, 345-352
   Abstract »    PDF »
Efficacy and Tolerability of Second-Generation Antipsychotics in Children and Adolescents With Schizophrenia.
S. Kumra, J. V. Oberstar, L. Sikich, R. L. Findling, J. M. McClellan, S. Vinogradov, and S. Charles Schulz (2008)
Schizophr Bull 34, 60-71
   Abstract »    Full Text »    PDF »
Antipsychotic-Induced Obesity: Histamine May Be the Key.
Journal Watch Psychiatry 2007, 2
   Full Text »
Illuminating the molecular basis for some antipsychotic drug-induced metabolic burden.
H. Y. Meltzer (2007)
PNAS 104, 3019-3020
   Full Text »    PDF »

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882